Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.

PURPOSE In recent studies, we showed that TP53 gene mutation or high levels of cytosolic vascular endothelial growth factor (VEGF) in estrogen receptor (ER)-alpha-positive primary breast tumors predict a poor disease outcome for patients treated with first-line tamoxifen for advanced disease. Mutant TP53 may up-regulate VEGF, whereas, on the other hand, wild-type TP53 may decrease VEGF production. EXPERIMENTAL DESIGN In the present study, we aimed to assess the combined predictive value of TP53 gene mutation and VEGF status of 160 advanced breast cancer patients with ER-positive tumors who were treated with tamoxifen (median follow-up from start of tamoxifen treatment, 64 months). To assess TP53 gene mutation status, the entire open reading frame was sequenced; for VEGF status, an ELISA was used. RESULTS In univariate analysis, both TP53 gene mutation (28% of the tumors) and a VEGF level above the median value were significantly associated with a short progression-free survival, post-relapse overall survival, and a poor rate of response to tamoxifen. In Cox multivariate regression analysis including the traditional predictive factors, the addition of TP53 gene mutation and VEGF status, alone or in combination, significantly predicted a poor efficacy of tamoxifen treatment. When the two factors were combined, a significantly decreased odds ratio was seen for the rate of response (odds ratio, 0.27). Similarly, an increased hazard ratio (HR) was seen for progression-free survival (HR, 2.32) and post-relapse overall survival (HR, 1.68) in the group with mutant TP53 and high VEGF compared with the group with both risk factors absent. CONCLUSIONS Combined TP53 gene mutation status and high VEGF levels of ER-positive primary breast tumors independently predict a poor course of the disease of patients with advanced breast cancer treated with tamoxifen. These patients, having unfavorable tumor characteristics, might benefit more from other types of (individualized) treatment protocols.

[1]  C. Osborne,et al.  Steroid hormone receptors in breast cancer management , 2004, Breast Cancer Research and Treatment.

[2]  S. Hyder.  The role of steroid hormones on the regulation of vascular endothelial growth factor. , 2002, The American journal of pathology.

[3]  J. Foekens,et al.  Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance , 2002, British Journal of Cancer.

[4]  J. Ingle,et al.  Endocrine Therapy in Breast Cancer , 2002 .

[5]  J. Foekens,et al.  Other Endocrine and Biological Agents in the Treatment of Advanced Breast Cancer , 2002 .

[6]  D. Hicklin,et al.  Effect of p53 Status on Tumor Response to Antiangiogenic Therapy , 2002, Science.

[7]  M. Toi,et al.  Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. , 2001, The Lancet. Oncology.

[8]  D. Mukhopadhyay,et al.  Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. , 2001, Cancer research.

[9]  T. H. van der Kwast,et al.  High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. , 2001, Cancer research.

[10]  Caroline Lohrisch,et al.  The Predictive Value of HER2 in Breast Cancer , 2001, Oncology.

[11]  T. Lindahl,et al.  The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. , 2001, Cancer research.

[12]  V. Jordan,et al.  Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  G. Stancel,et al.  Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. , 2000, Cancer research.

[14]  R Bicknell,et al.  Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. , 2000, Cancer research.

[15]  R. Vossen,et al.  Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. , 2000, Cancer research.

[16]  M. Karkkainen,et al.  Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells , 1999, Molecular and Cellular Endocrinology.

[17]  P. Vermeulen,et al.  Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. , 1999, The cancer journal from Scientific American.

[18]  A. Brodie,et al.  Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. , 1996, Endocrinology.

[19]  J. Foekens,et al.  Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. , 1995, Journal of the National Cancer Institute.

[20]  Erwin G. Van Meir,et al.  Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells , 1994, Nature Genetics.

[21]  J G Klijn,et al.  The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. , 1992, Endocrine reviews.